Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol for inflammation in high-risk cardiovascular patients
NCT01012414Phase 3Terminated
- Sponsor
- Thomas Jefferson University
- Start
- Jan 2010
- Primary completion
- May 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of paricalcitol oral solution in coronary artery disease (CAD), chronic kidney disease (CKD), sponsored by Thomas Jefferson University. Started Jan 2010; status: terminated.
02
Drugs
paricalcitol oral solution
03
Conditions
coronary artery disease (CAD)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT01012414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01012414.